Advertisement
Singapore markets closed
  • Straits Times Index

    3,426.47
    -3.98 (-0.12%)
     
  • Nikkei

    37,667.41
    -202.10 (-0.53%)
     
  • Hang Seng

    17,021.31
    +16.34 (+0.10%)
     
  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     
  • Bitcoin USD

    68,009.23
    +993.79 (+1.48%)
     
  • CMC Crypto 200

    1,372.40
    +41.79 (+3.14%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • Dow

    40,589.34
    +654.27 (+1.64%)
     
  • Nasdaq

    17,357.88
    +176.16 (+1.03%)
     
  • Gold

    2,385.70
    +32.20 (+1.37%)
     
  • Crude Oil

    76.44
    -1.84 (-2.35%)
     
  • 10-Yr Bond

    4.2000
    -0.0560 (-1.32%)
     
  • FTSE Bursa Malaysia

    1,612.88
    -2.30 (-0.14%)
     
  • Jakarta Composite Index

    7,288.17
    +47.89 (+0.66%)
     
  • PSE Index

    6,726.01
    +55.74 (+0.84%)
     

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex's forward multiple comes in at more than four times the upper bounds of this range. Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.